Recently, our company has reached a strategic cooperation with Boya united pharmaceutical institute CO.,LTD. on the Toutongding Syrup (100ml/bottle), to obtain the exclusive agency of the product.
MoreSumitomo became the strategic shareholder with shareholding of 29% held in C&O. C&O Board of Directors has been restructured and Sumitomo Corporation will appoint three directors to the C&O Board.
MoreThe Chinese government has recently included four new drug projects being developed by C&O in the major scientific and technological projects for “major new drug initiation”, the first program established by the Chinese government in the 11th Five-Ye
MoreOur existing R&D center in Nanjing will be relocated to a new, larger site in the Nanjing Xingang Economic and Technological Development Zone. The center covers a floor area of 26,668.3 m2 and has a built-up area of nearly 20,000 m2, with a capital i
MoreIn November 2008, C&O participated in the cefditoren licensing meeting organized by Meiji, a leading food and drug company in Japan, held in Tokyo, Japan. C&O has been Meiji’s designated distributor since January 2008 for the sale of its new generati
More
Address5/F, Jihao Building, 1086 Shennan East Road, Luohu District, Shenzhen
Adverse drug reactions / Event feedback hotline025-6816 1304
Adverse drug reactions / Event feedback mail[email protected]
Official WeChat account Mobile page